The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Widaplik
telmisartan, amlodipine and indapamide · TELMISARTAN 20 mg/1; AMLODIPINE BESYLATE 2.5 mg/1; INDAPAMIDE 1.25 mg/1 · Tablet · Oral · Azurity Pharmaceuticals, Inc.
NDC 24338-0002-30 · 30 TABLET in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA219423
- TE code
- —
- Approval date
- Jun 5, 2025
- Patents / exclusivity
- 5 patents, 3 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Jun 5, 2028 |
| exclusivity | NP | Jun 5, 2028 |
| exclusivity | NP | Jun 5, 2028 |
| patent | 12465599 | Jan 23, 2038 |
| patent | 10799487 | Jan 23, 2038 |
| patent | 12465599 | Jan 23, 2038 |
| patent | 12673047 | Jan 23, 2038 |
| patent | 10322117 | Jan 23, 2038 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of telmisartan, amlodipine and indapamide (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; INDAPAMIDE 2.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 10 mg/1; AMLODIPINE BESYLATE 1.25 mg/1; INDAPAMIDE .625 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 20 mg/1; AMLODIPINE BESYLATE 2.5 mg/1; INDAPAMIDE 1.25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 5 mg/1; AMLODIPINE BESYLATE 2.5 mg/1; INDAPAMIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 1.25 mg/1; AMLODIPINE BESYLATE .625 mg/1; INDAPAMIDE 10 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Azurity Pharmaceuticals, Inc. | TELMISARTAN 2.5 mg/1; AMLODIPINE BESYLATE 1.25 mg/1; INDAPAMIDE 20 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Azurity Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 5 mg/1; INDAPAMIDE 2.5 mg/1; TELMISARTAN 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Azurity Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 2.5 mg/1; INDAPAMIDE 1.25 mg/1; TELMISARTAN 20 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Azurity Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 1.25 mg/1; INDAPAMIDE .625 mg/1; TELMISARTAN 10 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Widaplik — NDC 24338-0002-30," retrieved September 3, 2026, https://drugdashboards.com/drug/24338000230.
Free to cite with attribution — see how the data is put together.